the clonogenic assay failed to discriminate between highly active in vivo antitumor agents and analogues with only marginal in vivo efficacy ( i.e. , doxorubicin and daunorubicin versus rhodomycins a and b , ametantrone versus nsc 276740 , cisplatin versus transplatin , [ au ( dppe ) 2 ] cl versus [ au ( depe ) 2 ] pf6 .
C0013089
doxorubicin
C0011015
daunorubicin